巴瑞替尼联合标准治疗用于有创机械通气或ECMO的危重型COVID-19住院成人:探索性随机安慰剂对照试验
COV-BARRIER探索性试验在18家医院纳入101例需有创机械通气或ECMO的危重型COVID-19成人,随机接受巴瑞替尼4mg每日一次或安慰剂联合标准治疗。
要点
- 巴瑞替尼降低危重型COVID-19机械通气或ECMO患者28天和60天死亡。
- 28天绝对风险降低19%,每6例治疗可避免1例死亡。
- 无呼吸机天数和住院时长两组无显著差异,安全性相似。
核心结论
- 在需有创机械通气或ECMO的危重型COVID-19住院成人中,巴瑞替尼联合标准治疗(含皮质激素)较安慰剂降低28天和60天死亡。
研究设计与样本
- 探索性、随机、双盲、安慰剂对照试验,在阿根廷、巴西、墨西哥和美国18家医院开展。
- 纳入101例年龄≥18岁、实验室确诊SARS-CoV-2感染且基线需有创机械通气或ECMO的住院成人,1:1随机接受巴瑞替尼4mg或安慰剂每日一次最多14天联合标准治疗。
- 主要预设终点包括28天和60天全因死亡、无呼吸机天数、住院时长和28天恢复时间;疗效分析基于意向治疗人群,安全性分析基于安全性人群。
主要发现
- 28天和60天每治疗6例巴瑞替尼组患者可较安慰剂组避免1例额外死亡。
关键数值与推荐
- 巴瑞替尼用法:4mg每日一次,最多14天,联合标准治疗。
- 标准治疗中87例(86%)参与者基线使用全身性皮质激素。
临床怎么用
- 对于需有创机械通气或ECMO的危重型COVID-19住院成人,可考虑在标准治疗(含皮质激素)基础上加用巴瑞替尼4mg每日一次最多14天以降低死亡。
- 治疗决策需结合探索性试验的局限性和较小样本量,等待进一步3期试验确认。
局限性
- 此为探索性试验,样本量相对较小(101例),需进一步3期试验确认 findings。
- 研究在阿根廷、巴西、墨西哥和美国18家医院开展,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a multinational, phase 3, randomised, double-blind, placebo-controlled trial of baricitinib in patients with confirmed SARS-CoV-2 infection. We aimed to evaluate the efficacy and safety of baricitinib plus standard of care in critically ill hospitalised adults with COVID-19 requiring invasive mechanical ventilation or extracorporeal membrane oxygenation. METHODS: This exploratory trial followed the study design of COV-BARRIER in a critically ill cohort not included in the main phase 3 trial. The study was conducted across 18 hospitals in Argentina, Brazil, Mexico, and the USA. Participants (aged ≥18 years) hospitalised with laboratory-confirmed SARS-CoV-2 infection on baseline invasive mechanical ventilation or extracorporeal membrane oxygenation were randomly assigned (1:1) to baricitinib (4 mg) or placebo once daily for up to 14 days in combination with standard of care. Participants, study staff, and investigators were masked to study group assignment. Prespecified endpoints included all-cause mortality through days 28 and 60, number of ventilator-free days, duration of hospitalisation, and time to recovery through day 28. The efficacy analysis was done in the intention-to-treat population and the safety analysis was done in the safety population. This trial is registered with ClinicalTrials.gov, NCT04421027. FINDINGS: Between Dec 23, 2020, and April 10, 2021, 101 participants were enrolled into the exploratory trial and assigned to baricitinib (n=51) or placebo (n=50) plus standard of care. Standard of care included baseline systemic corticosteroid use in 87 (86%) participants. Treatment with baricitinib significantly reduced 28-day all-cause mortality compared with placebo (20 [39%] of 51 participants died in the baricitinib group vs 29 [58%] of 50 in the placebo group; hazard ratio [HR] 0·54 [95% CI 0·31-0·96]; p=0·030; 46% relative reduction; absolute risk reduction 19%). A significant reduction in 60-day mortality was also observed in the baricitinib group compared with the placebo group (23 [45%] events vs 31 [62%]; HR 0·56 [95% CI 0·33-0·97]; p=0·027; 44% relative reduction; absolute risk reduction 17%). In every six baricitinib-treated participants, one additional death was prevented compared with placebo at days 28 and 60. The number of ventilator-free days did not differ significantly between treatment groups (mean 8·1 days [SD 10·2] in the baricitinib group vs 5·5 days [8·4] in the placebo group; p=0·21). The mean duration of hospitalisation in baricitinib-treated participants was not significantly shorter than in placebo-treated participants (23·7 days [SD 7·1] vs 26·1 days [3·9]; p=0·050). The rates of infections, blood clots, and adverse cardiovascular events were similar between treatment groups. INTERPRETATION: In critically ill hospitalised patients with COVID-19 who were receiving invasive mechanical ventilation or extracorporeal membrane oxygenation, treatment with baricitinib compared with placebo (in combination with standard of care, including corticosteroids) reduced mortality, which is consistent with the mortality reduction observed in less severely ill patients in the hospitalised primary COV-BARRIER study population. However, this was an exploratory trial with a relatively small sample size; therefore, further phase 3 trials are needed to confirm these findings. FUNDING: Eli Lilly and Company.
引用
- Ely EW, Ramanan AV, Kartman CE, et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial. Lancet Respir Med. 2022. PMID: 35123660. doi:10.1016/S2213-2600(22)00006-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。